Efficacy and Safety of Ropeginterferon Alfa-2b in Pregnant Women With Myeloproliferative Neoplasms: Case Series of Three Subtypes and Review.
Hangyeol Kim, Sung-Eun Lee, Young Rok Do et al.
✦ AI-curated · Sources linked
Case in brief
This case series reports on four pregnancies in women with myeloproliferative neoplasms (MPNs), including prefibrotic myelofibrosis, essential thrombocythemia, and polycythemia vera. Ropeginterferon alfa-2b was administered during pregnancy or prior to conception, alongside aspirin and/or low-molecular-weight heparin. All pregnancies resulted in live births, with sustained hematologic responses and no significant maternal or neonatal complications.
Diagnostic / clinical pearl
Ropeginterferon alfa-2b may be a viable cytoreductive treatment option for managing myeloproliferative neoplasms during pregnancy, as evidenced by sustained hematologic responses and favorable outcomes in this case series.